סודיום כלוריד % 0.9 לעירוי לתוך הוריד bp
teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride
רוקונסט - אבקה לתמיסה להזרקה
kamada ltd, israel - conestat alfa - אבקה להכנת תמיסה לזריקה - conestat alfa 2100 u/vial - conestat alfa
לוסרדקס 50
dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric
לוסרדקס 50
dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric
לוסרדקס 100
dexcel pharma technologies ltd - losartan potassium - קפליות - losartan potassium 100 mg - losartan - losartan - hypertension. losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losardex on the primary deposite endpoi
לוסרדקס 100
dexcel pharma technologies ltd - losartan potassium - קפליות - losartan potassium 100 mg - losartan - losartan - hypertension. losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended.renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losardex on the primary deposite endpoin
טיאסר 50 מ"ג
bioavenir ltd - losartan as potassium 50 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin
טיאסר 100 מ"ג
bioavenir ltd - losartan as potassium 100 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin
סנדוסטטין 30 מג lar
novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.
סנדוסטטין 20 מג lar
novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.